NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis

in Endocrine Connections
View More View Less
  • 1 A Malczewska, Department of Endocrinology and Neuroendocrine Tumors, Medical University of Silesia, Katowice, 40-055, Poland
  • 2 K Oberg, Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
  • 3 B Kos-Kudła, Department of Endocrinology and Neuoroendocrine Tumors, Medical University of Silesia, Katowice, Poland

Correspondence: Anna Malczewska, Email:

Introduction: The absence of a reliable, universal biomarker is a significant limitation in neuroendocrine neoplasia (NEN) management. We prospectively evaluated two CgA assays, (NEOLISA, EuroDiagnostica,) and (CgA ELISA, Demeditec Diagnostics (DD)) and compared the results to the NETest.

Methods: NEN cohort (n=258): pancreatic, n=67; small intestine, n=40; appendiceal, n=10; rectal, n=45; duodenal, n=9; gastric, n=44; lung, n=43. Image-positive disease (IPD) (n=123), image and histology negative (IND) (n=106), and image negative and histology positive (n=29). CgA metrics: NEOLISA, ULN: 108ng/mL, DD: ULN: 99ng/mL. Data: mean ±SEM. NETest: qRT-PCR - multianalyte analyses, ULN: 20. All samples de-identified and assessed blinded. Statistics: Mann-Whitney U-test, Pearson correlation and McNemar-test.

Results: CgA positive in 53/258 (NEOLISA), 32 (DD) and NETest-positive in 157/258. In image positive disease (IPD, n=123), NEOLISA-positive: 33% and DD: 19%. NETest-positive: 122/123 (99%; McNemar’s Chi2=79-97, p<0.0001). NEOLISA was more accurate than DD (p=0.0003). In image negative disease (IND), CgA was NEOLISA-positive (11%), DD (8%), p=NS, and NETest (33%). CgA assays could not distinguish progressive (PD) from stable disease (SD) or localized from metastatic disease (MD). NETest was significantly higher in PD (47±5) than SD (29±1, p=0.0009). NETest levels in MD (35±2) were elevated versus localized disease (24±1.3, p=0.008).

Conclusions: NETest, a multigenomic mRNA biomarker, was ~99% accurate in the identification of NEN disease. The CgA assays detected NEN disease in 19-33%. Multigenomic blood analysis using NETest is more accurate than CgA and should be considered the biomarker standard of care.

If the inline PDF is not rendering correctly, you can download the PDF file here.


     European Society of Endocrinology

     Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 141 141 38
PDF Downloads 120 120 33